Cerdulatinib (formerly known as PRT2070 and PRT062070) is an oral bioactive, dual-targeted tyrosine kinase (JAK and Syk) inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk [spleen tyrosine kinase (SYK) and Janus kinase (JAK)], respectively.

Baricitinib phosphate, the phosphate salt of Baricitinib which is also known as LY3009104 or INCB028050 or trade name Olumiant, is a potent, selective, ATP competitive and orally bioavailable inhibitor of tyrosine-protein kinase JAK1 or JAK2.

Oclacitinib (formerly also known as PF-03394197) is a novel and potent inhibitor of JAK (Janus kinase) family members with IC50 values ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ranging from 36 to 249 nM.

Brepocitinib (PF-06700841) tosylate, the tosylate salt of Brepocitinib, is a conformationally constrained piperazinyl-pyrimidine-based, Type 1 ATP site inhibitor of TYK2 and JAK1 kinases with IC50 values of 23 nM and 17 nM respectively.

Curcumol is a selective, potent, naturally occuring and pure monomer isolated from Rhizoma Curcumaeis with potential antitumor activities.

FLLL32, a synthetic curcumin analog, is a novel and potent Janus kinases-JAK2/STAT3 inhibitor with potential antitumor activity.

Itacitinib adipate, the adipate salt of itacitinib which is also known as INCB39110, is a potent, selective and orally bioavailable inhibitor of JAK1 (Janus-associated kinase 1) with potential antineoplastic activity, currently in Phase II clinical trials for the treatment of myelofibrosis, rheumatoid arthritis and plaque psoriasis.

Decernotinib (VX509; VRT831509; adelatinib) is a novel, potent, selective, and orally bioavailable inhibitor of JAK3 (Janus associated kinase) with potential anti-inflammatory activities.

Abrocitinib (formerly known as PF04965842; PF-04965842; Cibinqo) is a novel, potent and orally bioavailable JAK1 (Janus Kinase 1) inhibitor with immunomodulatory and antiinflammatory effects.

G5-7 is a potent , orally active and selective JAK2 inhibitor.